HighField’s TLL-018 tops tofacitinib on ACR50 in Phase 3 RA
Late-breaking ACR data: JAK1/TYK2 inhibitor ginoxitinib posted a 73% ACR50 rate at week 24 versus 49.5% for tofacitinib.
What moved. HighField Biopharmaceuticals reported Phase 3 TARA results for ginoxitinib (TLL-018), a selective JAK1/TYK2 inhibitor, as a late-breaking oral at ACR Convergence 2026 in active rheumatoid arthritis after inadequate response or intolerance to at least one bDMARD, according to company materials released around the meeting.
The number. At week 24, ACR50 was 73.0% on ginoxitinib versus 49.5% on tofacitinib 5 mg BID (difference 23.5 percentage points; p<0.0001). The company says China Phase 3 RA topline was positive in April 2026, with CDE breakthrough therapy designation in July 2026; a CSU Phase 3 also read out positive in January 2026.
Why it matters. Head-to-head superiority language against a marketed JAK is rare and commercially loud. For industry readers, watch how safety (infections, herpes zoster, VTE) and prior JAK exposure (38.9% in this trial) are framed in filings—and whether overseas rights become a live BD conversation.
Industry information only—not medical or investment advice.
